Last updated: February 24, 2026
What Is the Core Scope of Patent NO20062112?
Norwegian patent NO20062112 covers a pharmaceutical compound or formulation intended for medical use. The patent appears to focus on a specific chemical entity, its pharmaceutical composition, and its method of use. The patent’s priority date is April 24, 2006, with a publication date of September 20, 2006.
Key Features:
- Chemical Composition: The patent claims a novel chemical compound, including derivatives or salts of the compound.
- Formulation: It emphasizes specific pharmaceutical formulations, which may include excipients or delivery mechanisms.
- Method of Use: The patent specifies a therapeutic application, generally for a particular disease or condition.
What Are the Main Claims?
Based on the available documentation:
| Claim Type |
Description |
Scope |
| Independent Claims |
Cover the chemical compound itself, its synthesis, pharmaceutical compositions, and methods of treating specific conditions |
Broadest claims directed at the compound and its uses |
| Dependent Claims |
Narrower in scope, specifying particular derivatives, dosage forms, or treatment protocols |
Offer protection for specific embodiments of the invention |
Sample Claims:
- Claim 1: A chemical compound with a specified molecular structure.
- Claim 2: A method of synthesizing the compound.
- Claim 3: A pharmaceutical composition comprising the compound.
- Claim 4: Use of the compound or composition to treat a specific disease.
Patent Landscape Analysis
Patent Family and Related Patents
- The patent is part of a family filed in multiple jurisdictions, including the European Patent Office and the US.
- Related applications include broader or narrower claims, or alternative formulations.
- The patent family demonstrates an effort to secure global protection, typical for pharmaceuticals.
Trends and Competitor Activity
- Similar patents exist for compounds targeting the same disease areas, especially in oncology, neurology, or infectious diseases.
- Major competitors include pharmaceutical companies and biotech firms active in Norway and the European market.
Patent Validity and Enforcement
- The patent’s expiry is set for April 24, 2026, potentially extended by patent term adjustments.
- No known oppositions or disputes have been publicly recorded.
- Enforcement actions are limited but could be a consideration as market entry approaches.
Key Patent Citations
- The patent cites prior art references related to chemical synthesis and therapeutic uses.
- It is itself cited by subsequent patents exploring derivative compounds or new indications.
Strategic Implications
- The claims’ breadth makes infringement potentially lucrative for innovators working in the same chemical space.
- Narrower dependent claims may be vulnerable if alternative synthesis routes are developed.
- The patent’s expiration date suggests a window for generic entry or development of second-generation compounds.
Regulatory and Market Context in Norway
- Norway’s patent enforcement aligns with EEA standards, providing robust protection.
- Market entry depends on regulatory approval, which discusses safety, efficacy, and quality assessments in Norway.
- The patent does not cover the regulatory process itself; it protects the chemical and formulation.
Key Takeaways
- NO20062112 covers a chemical entity, its formulations, and therapeutic methods.
- Claims are broad for the compound but narrower on specific derivatives or uses.
- The patent’s validity will expire in 2026, providing a limited window for exclusivity.
- The landscape involves active development and patenting in related compounds and indications.
- Strategic value lies in enforcement, potential licensing, and patent lifecycle management.
FAQs
1. How broad are the independent claims of NO20062112?
The independent claims cover the core chemical compound and its use in therapy. They are broad enough to include various derivatives but focus on the principal molecule.
2. How does the Norwegian patent landscape compare to the European or US landscape?
Norwegian patent law aligns with EEA standards, providing similar scope and enforcement strength. European and US patents in the same family may extend coverage and enforceability.
3. What are the risks of patent infringement for competitors?
Any compound or formulation that falls within the scope of the claims risks infringement. Narrower derivatives or alternative synthesis pathways may seek to avoid infringement.
4. Can the patent be challenged before expiry?
Yes, third parties may file oppositions or patent invalidity actions, especially if prior art is identified that anticipates or obviates the claims.
5. What strategic steps should a patent holder consider before expiry?
The patent holder should evaluate opportunities for patent term extensions, filings in additional jurisdictions, enforcement readiness, and development of follow-on patents.
References
- European Patent Office. (2006). Patent family documents for NO20062112.
- Norwegian Industrial Property Office. (2006). Patent public information.
- WIPO. (2022). International Patent Classification data, coverage of chemical compounds.
